All News

Pharmacists play a crucial role in preventing cardiometabolic conditions through screenings, risk assessments, and lifestyle interventions, enhancing public health.

Low-carbohydrate diets, education, and technology enhance glycemic control and well-being for adults with type 1 diabetes.

This announcement is another move stemming from the federal government's skeptic views on vaccine technology and its efficacy among US patients.

Pharmacists enhance chronic disease management through patient-focused care, utilizing strategies like medication therapy management and community partnerships.

With OTC drug abuse on the rise, particularly among young people, researchers want to better understand ways to prevent it.

Vaccine hesitancy rises as new recommendations emerge, highlighting pharmacists’ crucial role in addressing misinformation and improving immunization rates.

Pharmacists enhancing chronic disease management through personalized care, education, and community collaboration.

Pharmacists play a crucial role in winter health, offering vaccinations, managing chronic conditions, and combating misinformation to keep communities healthy.

Researchers want to bolster evidence regarding the known link between maternal mental health and childhood nutritional status.

Multifaceted antimicrobial stewardship initiatives significantly enhance antibiotic prescribing practices for respiratory infections, improving patient outcomes.

Researchers explore community-acquired pneumococcal-related hospital admissions among adults from 2000 to 2019 and assess pneumococcal immunization’s impact after the year 2015.

In an exploration of the National Retail Data Monitor, researchers determine how OTC sales contributed to disease surveillance.

Person-centric packaging enhances medication adherence for type 2 diabetes patients, simplifying therapy and improving outcomes, according to recent studies.

John C. Goodman, PhD, discusses TrumpRx’s impact on patients and pharmacies, comparing this administration’s approach with the previous Biden Administration.

Dietary nutrients show promise in reducing asthma risk linked to indoor air pollution, offering new strategies for pharmacists in patient care.

The agency’s findings spur promises of significant change to the development and recommendations surrounding various immunizations.

Researchers investigate serotype distribution and antimicrobial resistance among children in Mexico with pneumococcal meningitis.

Morgan McSweeney, PhD, discusses America's public health decision-making, urging reforms to combat misinformation and safeguard scientific integrity in health agencies.

Conflicting federal health guidance creates confusion and erodes public trust, impacting patient safety and access to vital medical interventions.

Researchers conduct a cost-effectiveness analysis to uncover the public health and economic impacts of PCV20 among Australian children.

Novo Nordisk announced results of the evoke and evoke+ phase 3 trials on semaglutide’s use in treating Alzheimer disease progression.

Key sessions from the National Community Pharmacists Association 2025 Annual Convention & Expo highlight pharmacy benefit manager reform, pneumococcal vaccines, and billable services.

Tardive dyskinesia presents significant challenges for patients, but new FDA-approved treatments offer hope for improved management and quality of life.

Catie Stimmel, PharmD, explores the confidentiality and non-punitive processes that are crucial in driving value toward patient safety organizations.

Experts at the Milken Institute address better ways of adopting pharmacy services within the greater health care ecosystem.

After nearly 20 years of pneumococcal conjugate vaccine use in the Portuguese vaccine schedule, researchers explore serotype distribution in bacteria causing adult invasive pneumococcal disease (IPD).

The CDC states that the claim “vaccines do not cause autism” is not evidence based because studies have not ruled out the possibility that infant vaccines cause autism.

Regeneron Pharmaceuticals’ newest drug will be the first and only approved flexible treatment option for retinal vein occlusion.